Therefore, raloxifene was associated with a statistically highly significant suppression of bone resorption markers osteocalcin (−26.3%) and urinary cross-linked N-telopeptides of type I collagen (NTX) (−34%), 40 and both newly synthesized (ααCTX) and mature (ββCTX) collagen type I degradation. 41 Efficacy In the first “over 1000 participants” raloxifene trial, in 1145 healthy postmenopausal women aged 45 through 60 years the lumbar spine BMD increased from baseline to 36 months by 1.28 ± 0.23%.
← all excerpts
Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update.
1
—
—